Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective

• Published in: Cardiovascular drugs and therapy 2021-08, Vol.35 (4), p.775-785
• Main Authors: Liang, Zhe, Chen, Qi, Yang, Fei, Yan, Xianliang, Zhang, Xuehui, Chen, Xue, Fang, Fang, Zhao, Quanming
• Format: Article
• Language: English
• Subjects: Age; Antibodies, Monoclonal, Humanized - economics; Antibodies, Monoclonal, Humanized - therapeutic use; Cardiology; Cerebral infarction; China - epidemiology; Cholesterol; Cholesterol, LDL - blood; Cost analysis; Cost-Benefit Analysis - methods; Cost-Benefit Analysis - statistics & numerical data; Decision analysis; Demographics; Demography; Drug Costs; Female; Heart attacks; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II - blood; Hyperlipoproteinemia Type II - drug therapy; Hyperlipoproteinemia Type II - epidemiology; Kexin; Lipid Regulating Agents - economics; Lipid Regulating Agents - therapeutic use; Lipids; Low density lipoprotein; Male; Markov Chains; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Mortality; Myocardial infarction; Myocardial Infarction - blood; Myocardial Infarction - mortality; Myocardial Infarction - prevention & control; Original Article; Patients; PCSK9 Inhibitors - economics; PCSK9 Inhibitors - therapeutic use; Placebos; Proprotein convertases; Quality-Adjusted Life Years; Risk management; Risk reduction; Subtilisin; Utilities
• ISSN: 0920-3206; 1573-7241
• DOI: 10.1007/s10557-020-07079-6

Purpose Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an indispensable lipid-lowering treatment option, but their cost-effectiveness has been questioned. This study aimed to perform a health economic evaluation of evolocumab versus placebo in patients with myocardial infarction (MI) in China. Methods A Markov cohort state-transition model was developed in decision analysis software to estimate the incremental cost-effectiveness ratio (ICER), defined as cost per quality-adjusted life-year (QALY) saved. The simulation subjects could undergo non-fatal MI and/or stroke, or vascular or non-vascular death event. We integrated the Chinese population-specific demographics and event rates with the risk reduction of evolocumab based on the FOURIER trial and/or lowering of low-density lipoprotein cholesterol (LDL-C). Age-related change, event costs and utilities were included from published sources. Results At its current list price [33,748 Chinese yuan (CNY) annually per person], the ICER for evolocumab therapy was 927,713 CNY per QALY gained when integrating the FOURIER trial with absolute reduction of LDL-C. The probability of cost-effectiveness of evolocumab versus placebo was 1.96%, with a generally accepted threshold of 212,676 CNY per QALY gained. A reduction in acquisition price by approximately 70% (to less than 10,255 CNY annually) was needed to be cost-effective. Alternative scenario analyses of therapeutic benefit showed that the ICER for evolocumab in MI patients with uncontrolled familial hypercholesterolemia (FH) was 187,736 CNY per QALY gained. Conclusion Evolocumab in patients with MI was not cost-effective based on the price in 2019 in China; however, treatment with evolocumab was more favorable in MI patients with FH.